Onyx Pharmaceuticals, Inc.

  • Amgen: Onyx Pharmaceuticals Is Worth A Few Dollars More...

    By Amod Saul - August 7, 2013 | Tickers: AMGN, JNJ, ONXX

    It seems Amgen (NASDAQ: AMGN) has decided that Onyx Pharmaceuticals (NASDAQ: ONXX) is worth a few dollars more than the $120 per share it offered a few weeks ago. News agencies are filled with anonymously sourced reports that Amgen is planning to raise its bid to $130 per share.

    If accepted, the acquisition would give Amgen full rights to Onyx's Kyprolis (carfilzomib), a small molecule injectable proteasome inhibitor approved more »

  • A Closer Look at the Battle Over Cancer Treatments

    By Leo Sun - August 6, 2013 | Tickers: AMGN, INO, MRK, ONXX, PFE

    Over the past year, the battle over cancer treatments has heated up considerably. Big pharma companies such as Amgen (NASDAQ: AMGN), Pfizer (NYSE: PFE) and Merck (NYSE: MRK) are struggling to avoid the upcoming patent cliff by acquiring companies with promising oncology treatments. In this article, I’ll take a look at several of the key companies to follow in this field, and what investors can expect from this fast more »

  • This Orphan Drug Company Only Appears Expensive

    By Kanak Kanti - August 5, 2013 | Tickers: ALXN, ONXX, RHHBY

    In the last couple of months, we saw two big offers being made - and rejected - in the biotech sector. Both times, the companies that rejected these offers saw huge spikes in their respective stocks. Alexion (NASDAQ: ALXN) rejected an informal takeover proposal from Roche (NASDAQOTH: RHHBY) and went up 7%. Earlier, Onyx (NASDAQ: ONXX) rejected Amgen’s takeover bid and went up 50%.

    Investors generally need not worry that these more »

  • Will This Orphan Drug Maker Find a New Home?

    By Bob Chandler - August 5, 2013 | Tickers: ALXN, ALNY, ONXX

    Alexion Pharmaceuticals (NASDAQ: ALXN), already quite expensive, spiked higher since takeover rumors surfaced in early July. But can a deal give the stock another boost? I’m doubtful. Even if there is a buyout, which is not a certainty, I think it's probable that the company won’t command a much higher valuation than the current price. Saying that, there are also very good reasons I could be wrong more »

  • Will This Biotech Bidding War Lead You to Larger Gains?

    By Sherrie Stone - July 24, 2013 | Tickers: AMGN, AZN, NVS, ONXX, PFE

    Onyx Pharmaceuticals (NASDAQ: ONXX) added 3% to its one-month 60% gains on Monday because of continued speculation of a buyout. Reportedly, four companies are prepping bids to acquire Onyx. What is a fair price for the company, and should you buy now?

    Why the Interest?

    If $120 a share significantly undervalues the company, according to Onyx, then what is a fair price? This question can only be answered when you more »

  • Expanding Labels to Expand Margins

    By Seth Robey - July 18, 2013 | Tickers: ABBV, AMGN, CELG, JNJ, ONXX, PFE

    In an industry where buyouts are commonplace and small-cap biotechs burn through cash rapidly, optimizing operating cash flow can be essential to a company's financial health. Is cash being applied efficiently to maximize sales while minimizing the cost of R&D? Perhaps the most powerful way to maximize revenue potential and minimize cost is through label expansion.

    Companies with nascent revenue streams must appropriately limit costs while fostering newfound more »

  • Can This Biotech Go Even Higher?

    By Mohsin Saeed - July 18, 2013 | Tickers: CELG, ONXX

    Celgene (NASDAQ: CELG) has emerged as the leading treatment provider for blood cancer. The company value has almost doubled in the last year due to rising sales of Revlimid and approval of Pomalyst. Both drugs are amongst the leaders in this industry and have combined peak sales potential of more than $6 billion.

    According to recent news, Onyx Pharmaceuticals (NASDAQ: ONXX) is on the market and the street is speculating more »

  • Is The Orphan Drug Buying Frenzy Over?

    By Ben Williams - July 17, 2013 | Tickers: ACAD, AEGR, ALXN, ONXX, VRTX

    Orphan drug stocks may have been the hottest and best performing sector of the market for the past year, but they have really been on fire for the past month and have frequently been the object of takeover rumors. The big question is, “Can this buying frenzy be sustained; or is the rally over, at least for the time being, now that orphan drug stocks appear to be leveling off more »

  • A Fundamentally Strong Biotech Stock

    By Kanak Kanti - July 17, 2013 | Tickers: ABBV, BMY, CELG, ONXX

    Celgene (NASDAQ: CELG) surged 7% on Thursday, July 11, 2013 on news that the Phase III trials of Revlimid /dexamethasone combination showed that it could be an initial treatment for newly diagnosed multiple myeloma patients. This is indeed good news for the company after reports that Britain’s National Institute for Health and Care Excellence (NICE) may not recommend it for myelodysplastic syndromes in the U.K.

    Revlimid, Celegene’s more »

  • Betting on Blockbusters

    By Madhukar Dubey - July 17, 2013 | Tickers: JAZZ, ONXX, SGEN

    Global biotechnology industry revenue is expected to reach $262 billion this year showing growth of around 12.7% year over year. This industry has witnessed a rally in the stock price in the last year. This optimism around pharma and biotech companies will continue because of innovative drugs for unmet needs. Companies in this industry are focusing on R&D, which will help these companies create new drugs in the more »

  • Has Multiple Myeloma Met its Match?

    By Ryan Guenette - July 16, 2013 | Tickers: CELG, JNJ, ONXX, SNY

    Multiple myeloma is a cancer of plasma cells, a type of white blood cell present in bone marrow. This cancer can lead to abnormally high calcium levels, kidney failure, bone damage, and anemia-related fatigue. However, broad advancements are being made in treating the disease and Celgene (NASDAQ: CELG)(NASDAQ: CELG)(NASDAQ: CELG) is leading the charge.

    In a late stage study, its flagship blood-cancer drug Revlimid, assisted in extending the time in which more »

  • Who Could Buy Onyx and at What Price?

    By Kanak Kanti - July 12, 2013 | Tickers: BAYRY.PK, CELG, ONXX

    Note: This article has been amended to better reflect the development of each mentioned drug.

    Recently Onyx Pharmaceuticals (NASDAQ: ONXX) rejected a $10 billion takeover offer from Amgen. However, after that it hired an investment banker for finding a suitable buyer. With three cancer drugs in its portfolio, Onyx is an attractive takeover target for many larger biotechs. Investors want to consider if another offer or two is upcoming, and more »

  • Will This Biotech Acquisition Buzz Lead to More Buyouts?

    By Sherrie Stone - July 8, 2013 | Tickers: ARIA, ONXX, PCYC

    Onyx Pharmaceuticals (NASDAQ: ONXX) is trading higher after rejecting a takeover bid. As other stocks in its sector also trade higher in sympathy, will any of them become takeover targets, too?

    What’s Creating The Buzz

    The analysts, bloggers, and columnists were out in full force last Monday morning to assess the true “worth” of Onyx. The company markets cancer drugs Nexavar and Stivarga with Bayer, and solely develops Kyprolis more »

  • Who Is the Best Suitor for Onyx?

    By Vikas Shukla - July 8, 2013 | Tickers: AMGN, BAYRY.PK, ONXX

    Cancer-drug maker Onyx Pharmaceuticals (NASDAQ: ONXX) recently rejected an $8.7 billion unsolicited acquisition offer from Amgen (NASDAQ: AMGN). Onyx also said that it is looking for potential suitors. The move has triggered speculations of a bidding war, sending the stock up 51.27% on Monday to $131.33.

    Amgen had offered to pay $120 per share in cash, a 38.2% premium to Onyx’s closing price of $86 more »

  • Amgen Stirs the Pot in the Cancer-Related Sector

    By Phillip Woolgar - July 6, 2013 | Tickers: AMGN, ONXX, PCYC

    Several companies are fighting to be the first to release a treatment or cure for cancer that is a game-changer, and this battle has created a field where firms are looking to take any competitive advantage. The company that does manage to make the breakthrough that millions are waiting for will not only change the world, but also make a lot of shareholders very rich. 

    Amgen (NASDAQ: AMGN) in its more »

  • Is This Biopharmaceutical Stock Still a Buy?

    By Anh HOANG - July 4, 2013 | Tickers: AMGN, CELG, ONXX

    Onyx Pharmaceuticals (NASDAQ: ONXX) has recently experienced a significant jump of nearly 51.3% in only one trading day from $86.82 per share to $131.30 per share. The share price jump was due to the news that the company had received a $120 a share offer from Amgen (NASDAQ: AMGN) but rejected it as Onyx considered the offering price “significantly undervalued” the company. Let’s take a closer more »

  • Is This A Good Acquisition For All?

    By Brian Nichols - July 3, 2013 | Tickers: AMGN, GILD, ONXX

    For the second day in a row, the hot topic in the market is the bidding war for Onyx Pharmaceuticals (NASDAQ: ONXX). After rejecting Amgen’s (NASDAQ: AMGN) $120 a share offer, some analysts are predicting the bidding war could reach $160. While many have come to the defense of Amgen, saying that $160 is too much, I think we should look back on recent history as proof that this more »

  • Avoid This Biotech Investment, For Now

    By Mohsin Saeed - July 3, 2013 | Tickers: AMGN, BAYRY.PK, ONXX

    Mergers and acquisitions have always been a big part of the biotechnology industry, and the patent cliff has further increased M&A activity. We are only mid-way into 2013, but the biotech industry has already seen M&A of over $93.6 billion, as the generic threat and empty pipelines are forcing big-pharmaceutical players to adopt aggressive M&A strategies.

    Onyx Pharmaceuticals (NASDAQ: ONXX) has said that it has rejected more »

  • Onyx Bidding Wars: Who Would Be the Best Suitor?

    By usman iftikhar - July 2, 2013 | Tickers: AMGN, CELG, GILD, ONXX

    A lot of activity is happening in the biotech industry which would change the dynamics of the large cancer related drug makers.

    Recently, Amgen (NASDAQ: AMGN) made a surprisingly low offer to acquire the pharmaceutical company Onyx (NASDAQ: ONXX). Amgen offered $120 per share or roughly $10 billion. Onyx rejected the offer right away and is looking for other buyers now. With a successful cancer drug in the market and more »

  • Should You Invest in These Cancer Treatment Biotechs?

    By Leo Sun - July 2, 2013 | Tickers: AMGN, IMGN, IMMU, ONXX, SGEN

    Today, cancer is the second leading cause of death in the United States, accounting for nearly a quarter of all deaths in the country. 1.7 million new cases of cancer are expected to be diagnosed in 2013, and nearly 1,600 people die from the disease daily. This makes the race to cure cancer one of the most important goals of the biotech industry, and recent developments indicate that more »

  • Page 1 of 2